Teleflex & Vascular Solutions v. Medtronic: Federal Circuit Vacates & Remands
Vascular Solutions, Arrow International, Teleflex Life Sciences, and Teleflex LLC brought a patent infringement action against Medtronic, Inc. and Medtronic Vascular over coaxial guide catheter technology used in interventional cardiology. The Federal Circuit vacated the lower court decision and remanded the case within 231 days of filing — sending seven asserted patents back for further proceedings.
Federal Circuit wipes the slate: Medtronic guide catheter ruling sent back
Vascular Solutions, LLC, Arrow International, LLC, Teleflex Life Sciences, LLC, and Teleflex, LLC (collectively, the Teleflex parties) filed Case No. 24-1398 at the Court of Appeals for the Federal Circuit on January 29, 2024, asserting seven patents — five reissue patents (USRE045380E, USRE045760E, USRE045776E, USRE046116E, USRE047379E) and two utility patents (US8048032B2, US8142413B2) — against Medtronic, Inc. and Medtronic Vascular, Inc. The patents cover coaxial guide catheter technology for interventional cardiology procedures, a product segment central to percutaneous coronary intervention.
The Federal Circuit issued its disposition on September 16, 2024, ordering the lower court ruling vacated and the case remanded. A vacatur at the appellate level means the decision below is nullified — it carries no precedential or preclusive weight — and the lower court must reconsider the matter in light of the Federal Circuit’s guidance. For Medtronic, any prior judgment in its favour is wiped; for the Teleflex parties, the remand revives the infringement action and provides a renewed opportunity to prevail on the merits.
At 231 days, the appellate timeline is consistent with a case resolved on a focused legal question rather than a full merits briefing cycle, suggesting the Federal Circuit may have identified a discrete legal error — such as claim construction, IPR estoppel, or damages methodology — without requiring exhaustive record review. The specific grounds for vacatur are not stated in the public docket data available, which limits further inference. What remains unknown from the public record is precisely which legal issue drove the vacatur and what instruction the Federal Circuit issued on remand.
Filing to Vacated and Remanded in 231 days
231 days from filing to Federal Circuit disposition — a relatively swift appellate resolution for a seven-patent medtech case
Federal Circuit vacates: what the remand means for both parties
Vacatur nullifies the lower decision — neither side holds a final win
When the Federal Circuit vacates a lower court decision, that judgment is stripped of legal effect. It cannot be cited as precedent, and any injunction, damages award, or invalidity finding it contained is wiped. The court typically couples vacatur with a remand, directing the lower tribunal to reconsider on corrected legal grounds. This is distinct from a reversal: the Federal Circuit is not substituting its own judgment on the merits but rather requiring the lower court to try again.
Lower ruling nullifiedTeleflex parties get a second chance on seven catheter patents
For Vascular Solutions, Arrow International, and the Teleflex entities, vacatur is a meaningful reprieve. Any adverse ruling — whether on infringement, validity, or damages — has been erased. The seven asserted patents remain in play. On remand, the Teleflex parties will have the opportunity to re-litigate the disputed issues under the corrected legal framework mandated by the Federal Circuit, potentially recovering a damages award or securing injunctive relief that was previously denied or incorrectly calculated.
Infringement action revivedMedtronic loses prior judgment protection; litigation risk resets
Medtronic, Inc. and Medtronic Vascular, Inc. face renewed exposure. Any lower court ruling in their favour — on invalidity, non-infringement, or damages limitation — has been vacated and cannot be relied upon. Medtronic must now defend the same coaxial guide catheter product line on remand under a potentially corrected legal standard. The case suggests the Federal Circuit identified a flaw in the analysis applied below, which could narrow Medtronic’s available defences going forward.
Prior judgment erasedInterventional cardiology catheter IP remains a live enforcement battleground
With seven catheter patents — predominantly reissue patents, which signal deliberate scope broadening post-grant — still active and the infringement action unresolved, competitors in the coaxial guide catheter and PCI catheter segments face continued uncertainty. Vacatur without a merits ruling keeps the IP landscape unsettled: no claim construction ruling is final, no invalidity finding stands. Companies designing, manufacturing, or distributing guide catheter extensions for interventional cardiology should treat this remand as a signal to refresh freedom-to-operate analysis.
FTO landscape remains unsettledFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vascular Solutions, LLC | Company | Medtech IP portfolio — interventional cardiology catheter device patents (Teleflex/Vascular Solutions group)Search in Eureka ↗ |
| Co-Plaintiff | Arrow International, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Teleflex Life Sciences, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Teleflex, LLC | Company | Search in Eureka ↗ |
| Defendant | Medtronic, Inc. | Company | Medtronic, Inc. and Medtronic Vascular, Inc. — global cardiac device manufacturerSearch in Eureka ↗ |
| Co-Defendant | Medtronic Vascular, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Gabriel Ferrante | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | J. Derek Vandenburgh | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | John Thomas Vitt Esq. | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Joseph W. Winkels | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Sanjiv P. Laud | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Seung Sub Kim | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Tara Catherine Norgard | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | William M. Jay | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Carlson, Caspers, Vandenburgh & Lindquist, PA | Law Firm | Representing Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Goodwin Procter LLP | Law Firm | Representing Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Mccurdy Laud, LLC | Law Firm | Representing Vascular Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Barbara Marchevsky | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Brittany Blueitt Amadi, Esq. | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Cara S. Donels | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | David P. Yin | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Kurt John Niederluecke | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Laura Lynn Myers | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark Christopher Fleming | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant law firm | Fredrikson & Byron PA | Law Firm | Representing Medtronic, Inc.Search in Eureka ↗ |
| Defendant law firm | Wilmer Cutler Pickering Hale & Dorr LLP | Law Firm | Representing Medtronic, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘VACATED AND REMANDED’ — means the lower tribunal’s decision carries no legal force. The appellate standard for vacatur typically requires identification of a reversible legal error: the panel found that the proceedings below were infected by a mistake of law sufficient to require fresh consideration. Critically, this is not a merits ruling for either party; the Federal Circuit has not determined infringement, validity, or damages. The remand instruction will govern the scope of proceedings below, and the specific legal error identified by the panel will shape which issues are open for re-examination.
USRE045380E and six co-asserted catheter patents — coaxial guide catheter portfolio
The seven asserted patents cover coaxial guide catheter technology used in interventional cardiology — specifically catheter-in-catheter systems designed to extend access to coronary vessels during percutaneous coronary intervention (PCI). Five of the seven are reissue patents (USRE045380E, USRE045760E, USRE045776E, USRE046116E, USRE047379E), a designation that indicates the original patents were surrendered and reissued with corrected or broadened claims after original grant. Two utility patents (US8048032B2 and US8142413B2) round out the portfolio. The application lineage traces to U.S. application numbers filed across multiple continuations, consistent with a strategy to build layered protection across device configurations and methods of use.
Guide catheter extension systems — commercially represented by products such as the GuideLiner catheter — occupy a strategically important niche in the PCI device market. The use of reissue patents suggests the Teleflex/Vascular Solutions portfolio was actively shaped to address competitor products that emerged after original filing, making these patents particularly potent enforcement tools. For Medtronic, which markets competing catheter systems, the breadth of the reissued claims represents a material product liability. For the broader sector, a portfolio of this depth — seven patents, predominantly reissued, covering both device and method claims — signals that the patent holder views catheter-in-catheter technology as a core proprietary position worth defending through multiple litigation cycles.
Should you run an FTO against USRE045380E and the Teleflex catheter portfolio?
Any company designing, manufacturing, or distributing coaxial guide catheters, guide catheter extensions, or catheter-assist devices for interventional cardiology procedures should treat this litigation as a direct FTO trigger. The Teleflex/Vascular Solutions portfolio spans seven patents across reissue and utility grants, meaning claim scope has been actively broadened post-grant. With the Federal Circuit remand leaving no final infringement or invalidity determination in place, the enforceability of each patent remains live. R&D teams developing next-generation PCI access tools, and procurement teams sourcing catheter extensions, face meaningful IP exposure until remand proceedings conclude.
PatSnap Eureka’s FTO Search Agent enables rapid landscape mapping across all seven asserted patents simultaneously — surfacing claim-level comparisons, identifying prior art that survived IPR scrutiny, and flagging continuation applications that may extend the portfolio further. Rather than commissioning sequential single-patent opinions, Eureka allows IP teams to run a consolidated freedom-to-operate analysis against the full Teleflex catheter estate, cross-referenced against Medtronic’s own defensive filings, so your team enters remand proceedings or product launch decisions with a current, portfolio-level risk assessment.
Run a freedom-to-operate analysis on USRE045380E to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in interventional cardiology patent litigation
Cases involving reissue patent enforcement and guide catheter technology at the Federal Circuit — comparable scope, appellate posture, and medtech sector context.
What this case signals for the interventional cardiology IP landscape
Seven patents, a Federal Circuit vacatur, and an unresolved remand — the guide catheter IP battle is far from over.
Reissue patents signal deliberate claim broadening — monitor scope carefully
Five of the seven patents in suit are reissue patents, suggesting the Teleflex parties deliberately sought broader or corrected claim scope after original issuance. Reissue patents can capture product iterations not covered by original claims. Any company in the PCI catheter space should audit its current product lines against the reissued claim sets, not just the original grants.
Vacatur without settled claim construction leaves the market in limbo
Until the lower court issues a final, affirmed claim construction on remand, no definitive boundary exists for these catheter patents. Product designers and procurement teams at hospitals and catheter OEMs should factor this uncertainty into roadmap decisions. A cleared FTO today may need revisiting once remand proceedings conclude.
Vascular v Medtronic — key questions answered
The Federal Circuit vacated the lower court decision, meaning it is nullified and carries no legal effect. The case was remanded — sent back to the lower tribunal — for reconsideration consistent with the Federal Circuit’s ruling. Neither party holds a final judgment on infringement or validity of the seven catheter patents at this stage.
Seven patents are asserted: reissue patents USRE045380E, USRE045760E, USRE045776E, USRE046116E, and USRE047379E, plus utility patents US8048032B2 and US8142413B2. All cover coaxial guide catheter technology for interventional cardiology procedures. The reissue patents indicate broadened or corrected claim scope relative to their original grant.
Reissue patents are obtained when a patentee surrenders the original patent to correct errors or broaden claims, subject to USPTO review. Five reissue patents in a single portfolio suggests a deliberate strategy to expand claim coverage — typically to capture competing products that entered the market after original filing. This makes reissue patents particularly significant in enforcement actions against established competitors like Medtronic.
Any prior ruling in Medtronic’s favour — on non-infringement, invalidity, or damages — has been wiped by the vacatur and cannot be relied upon. Medtronic must defend the coaxial guide catheter infringement claims afresh on remand, under the legal framework the Federal Circuit has directed. Prior invalidity arguments may also be constrained by IPR estoppel if inter partes review proceedings were filed.
The case was filed January 29, 2024 and closed September 16, 2024 — a span of 231 days. This is relatively swift for a seven-patent Federal Circuit appeal and is consistent with resolution on a discrete legal question, such as a claim construction error or improper legal standard, rather than a full fact-intensive merits review. The specific error identified is not stated in the public docket data available.
PatSnap Eureka searches patents and litigation data to answer instantly.